Sean McClain is the President, Founder, and Chief Executive Officer of Absci Corp, a company at the forefront of revolutionizing drug discovery through the use of artificial intelligence (AI). With a strong background in biotechnology and a vision for leveraging AI to accelerate the drug development process, McClain has been instrumental in positioning Absci as a leader in the industry. He holds a Bachelor of Science degree in Chemical Engineering from the University of California, Berkeley, and has accumulated extensive experience in the biopharmaceutical sector prior to founding Absci. Before establishing Absci, McClain worked in various capacities within the biotech industry, gaining insights into the challenges and inefficiencies of traditional drug discovery methods. His experience and foresight led him to found Absci in 2011, with the goal of harnessing the power of AI and machine learning to streamline the drug discovery process. Under his leadership, Absci has developed a unique integrated drug creation platform that combines AI, synthetic biology, and automation to rapidly design and optimize novel therapeutics. McClain's strategic vision and dedication to innovation have been pivotal in driving Absci's growth and success, attracting significant investments and partnerships with major pharmaceutical companies. As the CEO of Absci, Sean McClain plays a crucial role in guiding the company's overall direction and strategy. He oversees the development and implementation of Absci's cutting-edge technologies, ensuring that the company remains at the forefront of the AI-driven drug discovery revolution. McClain's leadership has been recognized with numerous accolades, including being named to the Forbes 30 Under 30 list in Healthcare in 2017. His commitment to advancing the field of drug discovery through AI continues to inspire Absci's team and the broader scientific community, as the company works towards its mission of accelerating the development of life-saving therapies.